AbCellera BiologicsABCL

AbCellera reported a loss of 18 cents per share last quarter, which was slightly more than the 14 cents analysts expected. The company reported no revenue for the period, but the real focus for this business is the cash it brings in from new deals and the progress of its drug programs.

The company signed two new partnerships with Jazz Pharmaceuticals and Vertex to help find new medicines for cancer and autoimmune diseases. These deals will add over $100 million in upfront cash to its balance sheet. This is important because AbCellera uses its technology to find drugs for other companies in exchange for a slice of future sales. It also expects to release results from a mid-stage human trial for its own program, ABCL635, later this month. For a company that relies on proving its technology works, these results and new deals are more important than quarterly profit numbers.

See the full quarter, and how our tracked metrics did

Source: 8-K filing

Key highlights

• Major cash infusion: The company secured over $100 million in upfront cash through two new partnerships with Jazz Pharmaceuticals and Vertex, which helps fund development without needing to sell more stock. The Jazz deal alone includes $84 million upfront and could pay out up to $792 million for each of the three programs if they hit certain goals.
• Revenue drop during transition: Total revenue fell to $4.1 million from $17.1 million a year ago, reflecting a shift away from older research fees toward long-term ownership in drug programs. Licensing and royalty revenue, which is the high-value part of the business, dropped from $10.4 million to just $149,000 this quarter.
• Shrinking program portfolio: The number of active programs with a stake in future profits fell to 35, down from 44 at the start of the year. This suggests the company is becoming more selective or partners are narrowing their focus to only the most promising drug candidates.
• Fewer molecules in clinical trials: There are now 12 molecules in clinical trials, meaning human testing, compared to 19 at the end of last year. While the company is focusing on higher-quality leads, having fewer shots on goal reduces the immediate chances of a major royalty payout.
• Upcoming trial results: Management expects to release top-line data, which are the first key results of a study, for its ABCL635 program in August 2026. This is a major milestone because it will provide the first clear evidence of whether one of their lead internal drug candidates actually works in patients.

Our take: A weak quarter for sales, but the massive new cash deals with Vertex and Jazz are the real story. While the drop in active clinical molecules is a concern, the $112 million in new upfront payments provides a huge safety net. This keeps the long-term plan of building a royalty-rich portfolio on track.